Stand Up To Cancer (SU2C), an initiative of the Entertainment Industry Foundation (EIF), has launched a new program, Catalyst, that will leverage support and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.
Catalyst brings together industry partners Merck, Bristol-Myers Squibb and Genentech for collaborative research studies using new pharmaceutical compounds under development or approved agents that can be investigated for other uses. Under a partnership with the American Association for Cancer Research (AACR), SU2C will issue a request for proposal (RFP) to the scientific community that will outline current treatments, available funding, and the estimated number of projects that will be supported.
"The new source of funding is very important and so is access to drugs and other materials. Cancer researchers face challenges in obtaining materials needed for clinical trials," said Phillip Sharp, Ph.D., chair of the SU2C Scientific Advisory Committee and institute professor at the Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology (MIT), in a press release. This program, he said, will also provide opportunities to engage in cancer research more widely available to the research community.